Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy

Science Translational Medicine

Volumn 4, Issue 116, 2012, Pages

  Andronesi, Ovidiu C ^a   Kim, Grace S ^a   Gerstner, Elizabeth ^b   Batchelor, Tracy ^b   Tzika, Aria A ^a   Fantin, Valeria R ^c   Vander Heiden, Matthew G ^d,e   Sorensen, A Gregory ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c AGIOS PHARMACEUTICALS   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYGLUTARIC ACID; DNA; GLUTAMIC ACID; GLUTAMINE; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; UNCLASSIFIED DRUG; ALPHA-HYDROXYGLUTARATE; GLUTARIC ACID DERIVATIVE; IDH1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; BRAIN BIOPSY; CANCER PATIENT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; EX VIVO STUDY; FALSE POSITIVE RESULT; FEMALE; GENE; GENE MUTATION; GENE TARGETING; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IN VIVO STUDY; ISOCITRATE DEHYDROGENASE 1 GENE; MALE; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHANTOM; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCHOOL CHILD; SENSITIVITY ANALYSIS; SPECTRAL EDITING MAGNETIC RESONANCE SPECTROSCOPY; TWO DIMENSIONAL CORRELATION MAGNETIC RESONANCE SPECTROSCOPY; TWO DIMENSIONAL HIGH RESOLUTION MAGIC ANGLE SPINNING MAGNETIC RESONANCE SPECTROSCOPY; AGED; BIOPSY; BRAIN TUMOR; ENZYMOLOGY; EPILEPSY; GENETICS; GLIOMA; IMAGE QUALITY; METABOLISM; METHODOLOGY; MIDDLE AGED; MUTATION; PATHOLOGY;

ADULT; AGED; BIOPSY; BRAIN NEOPLASMS; EPILEPSY; FEMALE; GLIOMA; GLUTARATES; HUMANS; ISOCITRATE DEHYDROGENASE; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MUTATION; PHANTOMS, IMAGING; YOUNG ADULT;

EID: 84855710482     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3002693     Document Type: Article

References (37)

1. D. W. Parsons, S. Jones, X. Zhang, J. C. H. Lin, R. J. Leary, P. Angenendt, P. Mankoo, H. Carter, I. M. Siu, G. L. Gallia, A. Olivi, R. McLendon, B. A. Rasheed, S. Keir, T. Nikolskaya, Y. Nikolsky, D. A. Busam, H. Tekleab, L. A. Diaz Jr., J. Hartigan, D. R. Smith, R. L. Strausberg, S. K. N. Marie, S. M. O. Shinjo, H. Yan, G. J. Riggins, D. D. Bigner, R. Karchin, N. Papadopoulos, G. Parmigiani, B. Vogelstein, V. E. Velculescu, K. W. Kinzler, An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812 (2008).
2. Cancer Genome Atlas Research Network, Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
3. H. Yan, D.W. Parsons, G. Jin, R. McLendon, B.A. Rasheed, W. Yuan, I. Kos, I. Batinic-Haberle, S. Jones, G.J. Riggins, H. Friedman, A. Friedman, D. Reardon, J. Herndon, K.W. Kinzler, V.E. Velculescu, B. Vogelstein, D.D. Bigner, IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765-773 (2009).
4. N. K. Kloosterhof, L.B. Bralten, H.J. Dubbink, P.J. French, M.J. van den Bent, Isocitrate dehydrogenase-1 mutations: A fundamentally new understanding of diffuse glioma? Lancet Oncol. 12, 83-91 (2011).
5. R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol. 119, 487-494 (2010).
6. E. R. Mardis, L. Ding, D.J. Dooling, D.E. Larson, M.D. McLellan, K. Chen, D.C. Koboldt, R.S. Fulton, K.D. Delehaunty, S.D. McGrath, L.A. Fulton, D.P. Locke, V.J. Magrini, R.M. Abbott, T.L. Vickery, J.S. Reed, J.S. Robinson, T. Wylie, S.M. Smith, L. Carmichael, J.M. Eldred, C.C. Harris, J. Walker, J.B. Peck, F. Du, A.F. Dukes, G.E. Sanderson, A.M. Brummett, E. Clark, J.F. McMichael, R.J. Meyer, J.K. Schindler, C.S. Pohl, J.W. Wallis, X. Shi, L. Lin, H. Schmidt, Y. Tang, C. Haipek, M.E. Wiechert, J.V. Ivy, J. Kalicki, G. Elliott, R.E. Ries, J.E. Payton, P. Westervelt, M.H. Tomasson, M.A. Watson, J. Baty, S. Heath, W.D. Shannon, R. Nagarajan, D.C. Link, M.J. Walter, T.A. Graubert, J.F. DiPersio, R.K. Wilson, T.J. Ley, Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361, 1058-1066 (2009).
7. L. Dang, D.W. White, S. Gross, B.D. Bennett, M.A. Bittinger, E.M. Driggers, V.R. Fantin, H.G. Jang, S. Jin, M.C. Keenan, K.M. Marks, R.M. Prins, P.S. Ward, K.E. Yen, L.M. Liau, J.D. Rabinowitz, L.C. Cantley, C.B. Thompson, M. G. Vander Heiden, S.M. Su, Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739-744 (2009).
8. K. E. Yen, M.A. Bittinger, S.M. Su, V.R. Fantin, Cancer-associated IDH mutations: Biomarker and therapeutic opportunities. Oncogene 29, 6409-6417 (2010).
9. Z. J. Reitman, G. Jin, E.D. Karoly, I. Spasojevic, J. Yang, K.W. Kinzler, Y. He, D.D. Bigner, B. Vogelstein, H. Yan, Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc. Natl. Acad. Sci. U.S.A. 108, 3270-3275 (2011).
10. R. N. Sener, L-2 hydroxyglutaric aciduria: Proton magnetic resonance spectroscopy and diffusion magnetic resonance imaging findings. J. Comput. Assist. Tomogr. 27, 38-43 (2003).
11. S. M. Goffette, T.P. Duprez, M.C. Nassogne, M.F. Vincent, C. Jakobs, C.J. Sindic, L-2-Hydroxyglutaric aciduria: Clinical, genetic, and brain MRI characteristics in two adult sisters. Eur. J. Neurol. 13, 499-504 (2006).
12. S. W. Provencher, Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 30, 672-679 (1993).
13. A. Naressi, C. Couturier, J.M. Devos, M. Janssen, C. Mangeat, R. de Beer, D. Graveron-Demilly, Java-based graphical user interface for the MRUI quantitation package. MAGMA 12, 141-152 (2001).
14. M. Mescher, H. Merkle, J. Kirsch, M. Garwood, R. Gruetter, Simultaneous in vivo spectral editing and water suppression. NMR Biomed. 11, 266-272 (1998).
15. R. R. Ernst, 2-Dimensional spectroscopy. Chimia 29, 179-183 (1975).
16. O. C. Andronesi, S. Ramadan, C.E. Mountford, A.G. Sorensen, Low-power adiabatic sequences for in vivo localized two-dimensional chemical shift correlated MR spectroscopy. Magn. Reson. Med. 64, 1542-1556 (2010).
17. 13C NMR study of 2-hydroxyglutaric acid and its lactone. Magn. Reson. Chem. 40, 533-536 (2002).
18. V. Govindaraju, K. Young, A.A. Maudsley, Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed. 13, 129-153 (2000).
19. K. S. Opstad, B.A. Bell, J.R. Griffiths, F.A. Howe, Toward accurate quantification of metabolites, lipids, and macromolecules in HRMAS spectra of human brain tumor biopsies using LCModel. Magn. Reson. Med. 60, 1237-1242 (2008).
20. S. Ramadan, O.C. Andronesi, P. Stanwell, A.P. Lin, A.G. Sorensen, C.E. Mountford, Use of in vivo two-dimensional MR spectroscopy to compare the biochemistry of the human brain to that of glioblastoma. Radiology 259, 540-549 (2011).
21. 1H NMR spectroscopy in vivo and in vitro. J. Neurochem. 63, 1538-1543 (1994).
22. 1H magnetic resonance spectroscopy for the discrimination of primary brain tumors. Invest. Radiol. 34, 230-235 (1999).
23. 1H HR-MAS and genomic analysis of human tumor biopsies discriminate between high and low grade astrocytomas. NMR Biomed. 22, 629-637 (2009).
24. O. Beckonert, M. Coen, H.C. Keun, Y. Wang, T. M. D. Ebbels, E. Holmes, J.C. Lindon, J.K. Nicholson, High-resolution magic-angle-spinning NMR spectroscopy for metabolic profiling of intact tissues. Nat. Protoc. 5, 1019-1032 (2010).
25. J. Near, R. Simpson, P. Cowen, P. Jezzard, Efficient g-aminobutyric acid editing at 3T without macromolecule contamination: MEGA-SPECIAL. NMR Biomed. 10.1002/nbm.1688 (2011).
26. 18FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro Oncol. 13, 307-316 (2011).
27. O. C. Andronesi, B.A. Gagoski, E. Adalsteinsson, A.G. Sorensen, Correlation chemical shift imaging with low-power adiabatic pulses and constant-density spiral trajectories. NMR Biomed. 10.1002/nbm.1730 (2011).
28. H. Zhu, R.A. Edden, R. Ouwerkerk, P.B. Barker, High resolution spectroscopic imaging of GABA at 3 Tesla. Magn. Reson. Med. 65, 603-609 (2011).
29. W. Xu, H. Yang, Y. Liu, Y. Yang, P. Wang, S.H. Kim, S. Ito, C. Yang, P. Wang, M.T. Xiao, L.X. Liu, W.Q. Jiang, J. Liu, J.Y. Zhang, B. Wang, S. Frye, Y. Zhang, Y.H. Xu, Q.Y. Lei, K.L. Guan, S.M. Zhao, Y. Xiong, Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of a-ketoglutaratedependent dioxygenases. Cancer Cell 19, 17-30 (2011).
30. S. C. Williams, M.A. Karajannis, L. Chiriboga, J.G. Golfinos, Von Deimling A., D. Zagzag, R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1α upregulation in adult glioma. Acta Neuropathol. 121, 279-281 (2011).
31. O. C. Andronesi, S. Ramadan, E.M. Ratai, D. Jennings, C.E. Mountford, A.G. Sorensen, Spectroscopic imaging with improved gradient modulated constant adiabaticity pulses on high-field clinical scanners. J. Magn. Reson. 203, 283-293 (2010).
32. 1H NMR spectroscopy. J. Magn. Reson. B 104, 1-10 (1994).
33. R. Gruetter, I. Tkác, Field mapping without reference scan using asymmetric echo-planar techniques. Magn. Reson. Med. 43, 319-323 (2000).
34. A. J. van der Kouwe, T. Benner, D. H. Salat, B. Fischl, Brain morphometry with multiecho MPRAGE. Neuroimage 40, 559-569 (2008).
35. Y. Y. Lin, P. Hodgkinson, M. Ernst, A. Pines, A novel detection-estimation scheme for noisy NMR signals: Applications to delayed acquisition data. J. Magn. Reson. 128, 30-41 (1997).
36. 1H MRS study of human high grade gliomas. NMR Biomed. 17, 191-205 (2004).
37. M. A. Thomas, N. Hattori, M. Umeda, T. Sawada, S. Naruse, Evaluation of two-dimensional L-COSY and JPRESS using a 3 T MRI scanner: From phantoms to human brain in vivo. NMR Biomed. 16, 245-251 (2003).